Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 10/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.34 |
| ▸ | BCL2 | P10415 | 3/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.34 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622241 | 0.80 | AKR1B1 (0.36) | AKR1B1ESR1ALBMCL1BCL2 | |
| SCHEMBL2622254 | 0.69 | AKR1B1 (0.46) | AKR1B1ESR1ALBMCL1BCL2 | |
| SCHEMBL10268835 | 0.66 | AKR1B1 (0.51) | AKR1B1ESR1ALBMCL1BCL2 | |
| SCHEMBL12856266 | 0.63 | ALB (0.42) | AKR1B1ESR1ALBMCL1BCL2 | |
| SCHEMBL2622252 | 0.58 | AKR1B1 (0.64) | AKR1B1ESR1ALBMCL1BCL2 | |
| SCHEMBL2622255 | 0.58 | ALB (0.51) | AKR1B1ESR1ALBMCL1BCL2 | |
| SCHEMBL7920277 | 0.56 | MCL1 (0.81) | AKR1B1ESR1ALBMCL1BCL2 | |
| SCHEMBL2622276 | 0.55 | ESR1 (0.35) | AKR1B1ESR1ESR2MCL1BCL2 | |
| SCHEMBL658224 | 0.54 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL6830345 | 0.54 | ESR1 (1.00) | ESR1ESR2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163805-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100069344-A1 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090092684-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | GEORGETOWN UNIVERSITY | 2009-04-09 | — | — | US | disclosed |
| US-20090082424-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | REGENTS OF THE UNIVERSITY OF MICHIGAN, THE | 2009-03-26 | — | — | US | disclosed |
| US-7432304-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092684-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | BCL2, BCL2L1, BCL2L2 | AKR1B1 1880/4885ESR1 2063/4885ESR2 294/4885 |
| US-20100069344-A1 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | BCL2L1, BCL2, BCL2L11 | AKR1B1 1397/4885ESR1 1664/4885ESR2 309/4885 |
| US-20090082424-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | BCL2, BCL2L1, BCL2L2 | AKR1B1 1880/4885ESR1 2063/4885ESR2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.